AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05159245
Drug: Tepotinib
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MET ex14
Trial: NCT05159245
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RAF
Trial: NCT05159245
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MEK1, MEK2
Trial: NCT05159245
Drug: Dabrafenib+Trametinib
RxNorm normalized name: Dabrafenib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RAF, MEK1, MEK2
Trial: NCT05159245
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: FGFR2
Trial: NCT04732949
Drug: SNG001
RxNorm normalized name: SNG001
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day
Trial: NCT04929652
Drug: Surufatinib,Camrelizumab,Irinotecan,GM-CSF
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Dose climbing stage design (n=12) :~   Surufatinib: Oral, 3w.The initial dose of 250mg/ day (n=6) : If 2 out of 6 patients developed \> DLT in the first treatment cycle, the exploratory dose was 200 mg/ day; if ≤2 out of 6 patients developed DLT, the exploratory dose was 300mg/ day (n=6);At the next dose phase, if 2 out of 6 patients with \> developed DLT, the previous dose was recommended or the study was terminated;If no more than 2 out of 6 patients developed DLT, the dose was the recommended dose；PD-1,200mg, iv,D1, 3w；Irinotecan: 200mg/㎡, iv, D1, 3w；GM-CSF,D2, D3, D4, D5, D6 and D7 in the first week of each cycle ；~2. Dose expansion phase design(n=36):~   1. Surufatinib: Oral, 3w. the dose was set according to the recommended dose in the dose climbing stage;~  2. PD-1(Camrelizumab) : 200mg, iv,D1, 3w;~  3. Irinotecan: 200mg/㎡, iv, D1, 3w;~  4. GM-CSF: continuous administration of D2, D3, D4, D5, D6 and D7 in the first week of each cycle, 5ug/kg once per body weight, once a day, 3w.
Trial: NCT05365438
Drug: Omega 3-Atorvastatin
RxNorm normalized name: atorvastatin and omega-3 fatty acids
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atmeg 2 capsules with 1 pack of Omethyl cutielet
Trial: NCT05365438
Drug: Omega 3-Atorvastatin
RxNorm normalized name: atorvastatin and omega-3 fatty acids
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atmeg 2 capsules
Trial: NCT05365438
Drug: Atorvastatin-Ezetimibe
RxNorm normalized name: atorvastatin-ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ezetimibe/atorvastatin 10/20 mg
Trial: NCT05141721
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.
Trial: NCT05141721
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.
Trial: NCT05141721
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab administered as maintenance therapy per standard of care.
Trial: NCT04762134
Drug: Doxycycline Hyclate
RxNorm normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: STI PrEP arm: doxycycline capsules 100mg orally daily for 12 months STI PEP arm: doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
Trial: NCT04930887
Drug: Exparel (Bupivacaine Liposome)
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-opioid postsurgical analgesic used in the management of postsurgical pain; 133 mg/10 mL (13.3 mg/mL) single-dose vial (per Pacira), study administers 3cc bilaterally
Trial: NCT04930887
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prescription medicine used for fluid and electrolyte replenishment for intravenous administration; Exparel-matched Placebo treatment
Trial: NCT06416696
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Radiotherapy: Both external beam and brachytherapy, with radiation therapy techniques, target delineation, prescribed doses, and organ-at-risk constraints following established guidelines.~2. Chemotherapy: The preferred regimen is cisplatin at a dose of 40mg/m\^2 administered intravenously once weekly for 5-6 cycles; for patients intolerant to cisplatin or with renal impairment, carboplatin (AUC=2) may be considered, also administered once weekly.~3. Toripalimab concurrent immunotherapy: Following the regimens of phase III RCTs such as JUPITER-02, JUPITER-06, CHOICE-01, NEOTORCH, and RENOTORCH, Toripalimab is administered at a fixed dose of 240mg per infusion, given intravenously once every 3 weeks for three doses.~4. The concurrent chemoradiotherapy and immunotherapy phase does not exceed 8 weeks in duration.
Trial: NCT04836299
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomly assigned to receive a single 600 µg / kg dose of ivermectin or placebo.
Trial: NCT04809220
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered SC
Trial: NCT05471050
Drug: Danazol
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol is given at 200mg bid for 12 weeks.
Trial: NCT00215007
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05071703
Drug: Trilaciclib
RxNorm normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Carboplatin combined with Etoposide (ES-SCLC patients)~* plus Topotecan (second/third line ES-SCLC patients)
Trial: NCT04915404
Drug: Berubicin Hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Berubicin (DB17149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days).
Trial: NCT05242081
Drug: S-ketamine
RxNorm normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: S-ketamine 0.5mg/kg for induction and 0.2mg/kg/h for maintenance
Trial: NCT04829487
Drug: Ergocalciferol Capsules
RxNorm normalized name: Ergocalciferol Capsules
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given to subjects 50,000 IU per week for 8 weeks
Trial: NCT05351346
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT05351346
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT05351346
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Trial: NCT05351346
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
Trial: NCT05351346
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide PO will be administered as per the schedule specified in the respective arm.
Trial: NCT05351346
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT05791474
Drug: ATI-2231
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided by Aclaris Therapeutics, Inc.
Trial: NCT05371600
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam IV at 0.04 mg/kg
Trial: NCT04026984
Drug: Rifamycin SV-MMX
RxNorm normalized name: rifamycin SV
DrugBank: Rifamycin (DB11753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 Rifamycin SV-MMX® 50 mg tablets b.i.d. plus ORT
Trial: NCT05349149
Drug: Tocilizumab/Actemra® (Roche)
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The infusion of tocilizumab will antagonize IL-6 signaling for the duration of the study, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
Trial: NCT04917055
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of Saline behind knee using ultrasound guidance
Trial: NCT05375734
Drug: Tislelizumab in combination with anlotinib
RxNorm normalized name: Tislelizumab
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab：200 mg，ivgtt，d1，Q3W anlotinib： 10mg P.O d1-d14, Q3W
Trial: NCT06304090
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Trial: NCT05251376
Drug: Levomethadone HCl
RxNorm normalized name: levomethadone HCl
DrugBank: Levomethadone (DB13515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose given orally on Day 8 of the study.
Trial: NCT05251376
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily usual oral dose given on Day 1 and Day 2 of the study.
Trial: NCT05251376
Drug: Morphine Sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered daily and as needed from Day 3 of the study until subject back on usual daily methadone dose.
Trial: NCT05369351
Drug: Standard treatment+mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.
Trial: NCT05640570
Drug: The individualized Jade Wind-Barrier Herbal Tea Bag
RxNorm normalized name: BARRIER
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The individualized Jade Wind Barrier Herbal Tea Bag is composed of Astragali Radix (Zhi Huangqi) 4g, Saposhnikoviae Radix (Fangfeng) 2g, Atractylodes macrocephala Koidz (Baizhu) 2g, Nelumbinis Folium (Heye) 1g, Chrysanthemum morifolium Ramat (Juhua) 1g.
Trial: NCT06140095
Drug: Evolocumab
RxNorm normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: See arm description
Trial: NCT00000796
Drug: Cycloserine
RxNorm normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000796
Drug: Ethionamide
RxNorm normalized name: Ethionamide
DrugBank: Ethionamide (DB00609)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000796
Drug: Capreomycin sulfate
RxNorm normalized name: Capreomycin Sulfate
DrugBank: Capreomycin (DB00314)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000796
Drug: Aminosalicylic acid
RxNorm normalized name: Aminosalicylic Acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000796
Drug: Ethambutol hydrochloride
RxNorm normalized name: Ethambutol Hydrochloride
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000796
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000796
Drug: Pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000796
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000796
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000796
Drug: Clofazimine
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04879004
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Effect of continuous ESPB performed with Ropivacaine 0,375% infusion, in patients undergoing elective laparoscopic colectomy.
Trial: NCT06496009
Drug: PD-1 Inhibitors
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: advanced or metastatic non-small cell lung cancer who are PD-L1 negative and receiving first-line immunotherapy in routine clinical practice
Trial: NCT06423911
Drug: olverembatinib
RxNorm normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olverembatinib QOD
Trial: NCT06423911
Drug: Bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutnib QD
Trial: NCT05797493
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Upfront chemo-immunotherapy
Trial: NCT04745403
Drug: mRNA HBV/TCR T-cells
RxNorm normalized name: mRNA HBV/TCR T-cells
DrugBank: LioCyx-M004 (DB17368)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Infusion~The first dose of mRNA HBV-TCR T-cells at dose 1x10e5/kg BW will be infused on Day 0, and subsequently incremental doses on Day 14 and 28, up to the dose of 5-10x10e6/kg BW.
Trial: NCT05677542
Drug: secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: all patients who received secukinumab
Trial: NCT05588102
Drug: Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in the intervention group received SSRIs antidepressants combined with Electronic cognitive training based on mobile phone platform for 52 weeks (once a day, 60min each time)
Trial: NCT04327986
Drug: M9241
RxNorm normalized name: Moxidectin
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection on Day 1 of every cycle
Trial: NCT05366439
Drug: AT-752
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parallel Assignment
Trial: NCT04941508
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Children will be given a single bolus of dexmedetomidine 0.2 µ/kg IV at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
Trial: NCT05522465
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 4mg/kg.d, d1-4
Trial: NCT05522465
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 0.6mg/kg.d, d1-4
Trial: NCT04145258
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
Trial: NCT05828277
Drug: repotrectinib (TPX-0005)
RxNorm normalized name: Repotrectinib
DrugBank: Repotrectinib (DB16826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral repotrectinib (TPX-0005)
Trial: NCT05517499
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Randomized clinical trial
Trial: NCT06244862
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ruxolitinib twice a day (10 mg x 2 during 28 days) in association with standard of care in HS.
Trial: NCT05282719
Drug: venetoclax combined with azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
Trial: NCT05812014
Drug: 0.9% sodium chloride solution
RxNorm normalized name: Precedex 80mcg/20mL in 0.9% Sodium Chloride Solution for Injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One dose was administered by intramuscular injection, 1.0ml/dose
Trial: NCT05769959
Drug: tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).
Trial: NCT05507983
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 1500 mg
Trial: NCT00752882
Drug: ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02090127
Drug: ficlatuzumab
RxNorm normalized name: Ficlatuzumab
DrugBank: Ficlatuzumab (DB11680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator
Trial: NCT00002115
Drug: Adefovir
RxNorm normalized name: Adefovir
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05965856
Drug: BL-B01D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion
Trial: NCT05965856
Drug: SI-B003
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion
Trial: NCT04988217
Drug: Interferon-Alpha2B
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized interferon alpha 2B
Trial: NCT06209736
Drug: OMS906 study drug
RxNorm normalized name: ethanol
DrugBank: OMS906 (DB17722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OMS906 study drug dose 5mg/kg IV administration at 4-week internals
Trial: NCT04944901
Drug: SB-121
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-121 is a formulation of L. reuteri
Trial: NCT06045091
Drug: Human BCMA targeted CAR-NK cells injection
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogenic genetically modified anti-BCMA CAR transduced NK cells
Trial: NCT05595993
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will be allocated to receive oral administration of 200 mg cilostazol.
Trial: NCT05437289
Drug: AZD7442 IM
RxNorm normalized name: AZD7442
DrugBank: AZD7442 (DB15787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In cohort 1, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) administered sequentially as direct gluteal IM injections.
Trial: NCT05437289
Drug: AZD7442 IM
RxNorm normalized name: AZD7442
DrugBank: AZD7442 (DB15787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In cohort 2, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) administered sequentially as direct gluteal IM injections.
Trial: NCT05437289
Drug: AZD7442 IV
RxNorm normalized name: AZD7442
DrugBank: AZD7442 (DB15787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In cohort 3, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
Trial: NCT05437289
Drug: AZD7442 IV
RxNorm normalized name: AZD7442
DrugBank: AZD7442 (DB15787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In cohort 4, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.